GoAI
Get started
Alumis Inc. logo

Alumis Inc.

ALMS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$24.17

+$1.31 · +5.73%

Aug 21, 4:00 PM ET

ALMS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

34

Expensive

Momentum

72

Gaining

Sentiment

58

Mixed

Risk resilience

61

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Martin Babler
Listed since
Jun 28, 2024
Employees
237

Market position

Day range

Current $24.17

52-week range

Current $24.17

Open
$22.98
Previous close
$22.86
Volume
934.81K
0.76× average
Average volume
1.23M
Average daily volume
Market cap
2.98B USD
Beta
-0.67
Market reference 1
50-day average
$26.4354
-8.57% below average
200-day average
$21.5498
+12.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
8.25B USD
P/E (TTM)
-6.36×
P/B (TTM)
6.83×
P/S (TTM)
403.26×
EV / EBITDA
-33.2×
Earnings yield
-2.93%
Free cash flow yield
-4.46%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
88.23%
Operating margin
-6204.39%
Net margin
-5933.45%
Return on equity
-80.76%
Return on assets
-59.07%
Return on invested capital
-120.21%

Financial health

Debt / equity
0.08×
Current ratio
4.34×
Altman Z-score
11.99
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−427.2M USD-42.04%

Net income

−243.33M USD+17.30%
Income trends across reported periods−80.4M USD−206.51M USD−332.62M USD−458.73M USDOperating income, FY2022: −113.85M USDOperating income, FY2023: −158.17M USDOperating income, FY2024: −300.75M USDOperating income, FY2025: −427.2M USDNet income, FY2022: −111.93M USDNet income, FY2023: −154.99M USDNet income, FY2024: −294.23M USDNet income, FY2025: −243.33M USDFY2022FY2023FY2024FY2025
Operating income FY2022 −113.85M USD. Operating income FY2023 −158.17M USD. Operating income FY2024 −300.75M USD. Operating income FY2025 −427.2M USD. Net income FY2022 −111.93M USD. Net income FY2023 −154.99M USD. Net income FY2024 −294.23M USD. Net income FY2025 −243.33M USD.
Metric (USD)FY2025FY2024FY2023FY2022
Revenue24.05M USD———
Cost of goods sold3.5M USD3.15M USD—250K USD
Gross profit20.55M USD−3.15M USD—−250K USD
Research and development386M USD265.55M USD137.68M USD101.05M USD
Selling, general, and administrative91.86M USD35.2M USD20.5M USD12.55M USD
Operating expenses447.76M USD297.6M USD158.17M USD113.6M USD
Interest income14.18M USD12.02M USD3.37M USD1.99M USD
Depreciation and amortization3.5M USD3.15M USD1.28M USD250K USD
Operating income−427.2M USD−300.75M USD−158.17M USD−113.85M USD
Net income−243.33M USD−294.23M USD−154.99M USD−111.93M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
22%
2 beats, 7 misses, 0 met estimates
Average EPS surprise
-13.02%
9 comparable reports
Latest EPS result
-1.11
Estimate -0.77 · Miss by 44.72%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.64-1.06-1.49-1.91Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual -1.74, estimate -1.4, surprise -24.29%, Miss. Q2 2025, reported May 14, 2025: actual -1.82, estimate -1.47, surprise -23.81%, Miss. Q3 2025, reported Aug 13, 2025: actual -1.17, estimate -1.11, surprise -5.41%, Miss. Q4 2025, reported Nov 13, 2025: actual -1.06, estimate -0.92, surprise -15.22%, Miss. Q1 2026, reported Mar 19, 2026: actual -0.95, estimate -0.97, surprise +2.06%, Beat. Q2 2026, reported May 14, 2026: actual -0.74, estimate -0.743, surprise +0.37%, Beat. Q3 2026, reported Aug 13, 2026: actual -1.11, estimate -0.767, surprise -44.72%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.73, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates18.7M12.75M6.8M850KQ1 '25EstimateQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 19, 2025: actual —, estimate 1M USD, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 17.39M USD, estimate 1.67M USD, surprise +943.34%, Beat. Q3 2025, reported Aug 13, 2025: actual 2.67M USD, estimate 3.14M USD, surprise -15.17%, Miss. Q4 2025, reported Nov 13, 2025: actual 2.07M USD, estimate 2.75M USD, surprise -24.87%, Miss. Q1 2026, reported Mar 19, 2026: actual 1.93M USD, estimate 2.36M USD, surprise -18.36%, Miss. Q2 2026, reported May 14, 2026: actual 1.74M USD, estimate 2.06M USD, surprise -15.41%, Miss. Q3 2026, reported Aug 13, 2026: actual 1.66M USD, estimate 3.65M USD, surprise -54.49%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate 1.9M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$39.17

62.06% upside
Past 12 months12-month forecastHigh $51.00Average $39.17Low $25.00

Recent analyst actions

8 institutions
Leerink PartnersmaintainOutperform
Cantor FitzgeraldmaintainOverweight

ALMS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALMS

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
89.06M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
46.29M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
27.75M
Weight
0.03%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
16.84M
Weight
0.11%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
14.29M
Weight
0.13%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
12.52M
Weight
0.07%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
9.32M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%
State Street SPDR S&P Pharmaceuticals ETF logoState Street SPDR S&P Pharmaceuticals ETFXPH
Market value
9.09M
Weight
1.62%
AUM
560.87M USD
Expense ratio
0.35%
Price / 1D
$72.80+0.71%

Continue in GoAI

Research ALMS

research.disclaimer